(99m)Tc hexamethyl-propylene-aminoxime single-photon emission computed tomography prediction of conversion from mild cognitive impairment to Alzheimer disease.
OBJECTIVE
To examine the utility of single-photon emission computed tomography (SPECT) to predict conversion from mild cognitive impairment (MCI) to Alzheimer disease (AD).


METHODS
Longitudinal, prospective study.


METHODS
University-based memory disorders clinic.


METHODS
One hundred twenty seven patients with MCI and 59 healthy comparison subjects followed up for 1-9 years.


METHODS
Diagnostic evaluation, neuropsychological tests, social/cognitive function, olfactory identification, apolipoprotein E genotype, magnetic resonance imaging, and brain Tc hexamethyl-propylene-aminoxime SPECT scan with visual ratings, and region of interest (ROI) analyses were done.


RESULTS
Visual ratings of SPECT temporal and parietal blood flow did not distinguish eventual MCI converters to AD (N = 31) from nonconverters (N = 96), but the global rating predicted conversion (41.9% sensitivity and 82.3% specificity, Fisher's exact test p = 0.013). Blood flow in each ROI was not predictive, but when dichotomized at the median value of the patients with MCI, low flow increased the hazard of conversion to AD for parietal (hazard ratio: 2.96, 95% confidence interval: 1.16-7.53, p = 0.023) and medial temporal regions (hazard ratio: 3.12, 95% confidence interval: 1.14-8.56, p = 0.027). In the 3-year follow-up sample, low parietal (p <0.05) and medial temporal (p <0.01) flow predicted conversion to AD, with or without controlling for age, Mini-Mental State Examination, and apolipoprotein E ε4 genotype. These measures lost significance when other strong predictors were included in logistic regression analyses: verbal memory, social/cognitive functioning, olfactory identification deficits, hippocampal, and entorhinal cortex volumes.


CONCLUSIONS
SPECT visual ratings showed limited utility in predicting MCI conversion to AD. The modest predictive utility of quantified low parietal and medial temporal flow using SPECT may decrease when other stronger predictors are available.
Devanand
D P
DP
NYSPI, Columbia University, New York, NY 10032, USA. dpd3@columbia.edu
Van Heertum
Ronald L
RL
Kegeles
Lawrence S
LS
Liu
Xinhua
X
Jin
Zong Hao
ZH
Pradhaban
Gnanavalli
G
Rusinek
Henry
H
Pratap
Mali
M
Pelton
Gregory H
GH
Prohovnik
Isak
I
Stern
Yaakov
Y
Mann
J John
JJ
Parsey
Ramin
R
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000544:Alzheimer Disease / Q000175:diagnosis* / Q000000981:diagnostic imaging / Q000473:pathology / Q000503:physiopathology; D053327:Apolipoprotein E4 / Q000235:genetics; D001284:Atrophy / Q000473:pathology; D001921:Brain / Q000098:blood supply* / Q000000981:diagnostic imaging / Q000473:pathology; D002560:Cerebrovascular Circulation / Q000502:physiology; D003072:Cognition Disorders / Q000175:diagnosis* / Q000000981:diagnostic imaging / Q000473:pathology / Q000503:physiopathology; D018450:Disease Progression; D005260:Female; D005838:Genotype; D006801:Humans; D008297:Male; D008875:Middle Aged; D010091:Oximes; D011237:Predictive Value of Tests; D019690:Technetium Tc 99m Exametazime; D015899:Tomography, Emission-Computed, Single-Photon / Q000379:methods*
D053327:Apolipoprotein E4; D010091:Oximes; C068296:hexamethylpropyleneamine oxime; D019690:Technetium Tc 99m Exametazime
Am J Psychiatry. 2002 Mar;159(3):474-6
11870015
J Nucl Med. 2008 Mar;49(3):390-8
18287270
Arch Neurol. 2005 Jun;62(6):975-80
15956169
Neurobiol Aging. 2006 Jan;27(1):24-31
16298237
Arch Gen Psychiatry. 2006 Aug;63(8):916-24
16894068
Am J Geriatr Psychiatry. 2004 Nov-Dec;12(6):554-70
15545324
Proc Natl Acad Sci U S A. 2005 Jun 7;102(23):8299-302
15932949
Neurology. 1984 Jul;34(7):939-44
6610841
Ann Neurol. 1997 Jul;42(1):85-94
9225689
BMC Neurol. 2002 Sep 12;2:9
12227833
Neuroimage. 2003 Jul;19(3):1137-44
12880839
Arch Neurol. 1992 May;49(5):453-60
1580806
AJNR Am J Neuroradiol. 2009 Feb;30(2):404-10
19001534
J Neurol Neurosurg Psychiatry. 2007 Mar;78(3):240-7
17056633
Biol Psychiatry. 2008 Nov 15;64(10):871-9
18723162
Neuroimage. 2005 Dec;28(4):1014-21
16129627
J Gerontol. 1982 May;37(3):323-9
7069156
Neurobiol Aging. 2001 Jul-Aug;22(4):529-39
11445252
J Neurol. 2005 Nov;252(11):1359-62
15965586
J Neuropsychiatry Clin Neurosci. 2003 Summer;15(3):326-32
12928508
Arch Neurol. 1999 Mar;56(3):303-8
10190820
J Nucl Med. 1999 Dec;40(12):2053-65
10616886
Neurology. 2007 Mar 13;68(11):828-36
17353470
J Alzheimers Dis. 2009;17(4):761-72
19542623
J Neurol. 2007 Dec;254(12):1698-707
17990057
Neurology. 2005 Jun 14;64(11):1860-7
15955934
Dement Geriatr Cogn Disord. 2007;24(6):429-33
17952007
Neurology. 2002 Mar 12;58(5):758-64
11889240
Neurology. 2003 Apr 22;60(8):1374-7
12707450
Open Neuroimag J. 2008;2:20-8
19018314
J Chem Neuroanat. 2000 Dec;20(3-4):215-24
11207420
JAMA. 2001 Nov 7;286(17):2120-7
11694153
Neurobiol Aging. 2007 Jul;28(7):1062-9
16824650
Neurobiol Aging. 2011 Jan;32(1):15-23
19250707
Eur J Nucl Med Mol Imaging. 2003 Nov;30(11):1473-80
14579086
Eur J Nucl Med Mol Imaging. 2003 Aug;30(8):1104-13
12764551
Med Sci Monit. 2007 May;13 Suppl 1:31-7
17507882
Neurobiol Aging. 2011 Jul;32(7):1207-18
19660834
Natl Vital Stat Rep. 2007 Aug 21;55(19):1-119
17867520
Eur J Nucl Med Mol Imaging. 2009 May;36(5):831-40
19148640